Zevra Therapeutics (ZVRA) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $199.5 million.
- Zevra Therapeutics' Cash & Current Investments rose 12322.44% to $199.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $199.5 million, marking a year-over-year increase of 12322.44%. This contributed to the annual value of $69.5 million for FY2024, which is 259.68% up from last year.
- Per Zevra Therapeutics' latest filing, its Cash & Current Investments stood at $199.5 million for Q3 2025, which was up 12322.44% from $202.6 million recorded in Q2 2025.
- Zevra Therapeutics' Cash & Current Investments' 5-year high stood at $202.6 million during Q2 2025, with a 5-year trough of $49.3 million in Q2 2024.
- Moreover, its 5-year median value for Cash & Current Investments was $82.4 million (2022), whereas its average is $96.3 million.
- In the last 5 years, Zevra Therapeutics' Cash & Current Investments surged by 312228.35% in 2021 and then crashed by 4331.12% in 2024.
- Zevra Therapeutics' Cash & Current Investments (Quarter) stood at $112.3 million in 2021, then decreased by 26.69% to $82.4 million in 2022, then fell by 17.76% to $67.7 million in 2023, then rose by 2.6% to $69.5 million in 2024, then surged by 187.08% to $199.5 million in 2025.
- Its last three reported values are $199.5 million in Q3 2025, $202.6 million for Q2 2025, and $62.6 million during Q1 2025.